Business Wire

ZS acquires bioinformatics and systems biology company, Intomics A/S

Share

The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics. Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development by enabling complex analysis of biomedical data. The addition of renowned scientists to the ZS team will strengthen ZS’s focus on the discovery of new medicines for all.

Global pharmaceutical and biotech companies, along with other biomedical research entities, use Intomics’s service and technology offerings to assist in preclinical work, including target discovery, biomarker identification, drug repositioning and patient stratification. As the pharmaceutical industry intensifies its efforts on developing novel drugs, demand for innovative capabilities in discovery and disease biology is growing.

Intomics’s highly curated and best-in-class protein-protein interaction network is condition-agnostic and supports tailored biomedical analysis spanning multiple diseases. Scientists and bioinformaticians use the network to understand disease biology at the pathway and molecular level. This drives novel insights and discoveries and accelerates preclinical activities to ultimately bring new medicines to patients faster.

“Our strategic acquisition of Intomics will allow us to assist our clients in pursuing breakthrough science and innovative medicines that profoundly improve patients’ lives,” said Pratap Khedkar, CEO of ZS. “Combined, our unique mix of deep data, academic and scientific expertise, technology and artificial intelligence will ultimately accelerate drug discovery and improve the probability of success for innovative medicines.”

The 42 members of Intomics will join ZS’s staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, data science and technology expertise with a research mindset to advance the adoption of in-silico methods in drug discovery. The addition of Intomics expands upon ZS’s existing data and technology offerings to bring further sophistication in leveraging analytics, bioinformatics and applied mathematics to drive business impact for the science of R&D.

“For us, ZS was a natural destination to build on our legacy. Through integration with ZS, we will be able to broaden our impact in drug discovery, increase the scale and use of AI in our client work and operate on a global scale while expanding career opportunities for our team members,” said Thomas S. Jensen, Ph.D., CEO and co-founder of Intomics. “Our shared roots in academia and shared values, including a commitment to rigor, a deliberative approach and doing right by both our clients and our staff, made ZS a natural fit for us and for our clients,” he continued.

About ZS

ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 12,000-plus ZSers in 30-plus offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.

About Intomics

Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers who share a passion for translating data to cures. And we’ve proudly done so for more than 10 years. We collaborate closely with our clients in the biotech and pharmaceutical industry, and we harness the synergy between our clients’ specific disease knowledge and our unique data analytics expertise and technology. Together we make a difference for patients. This is both our trademark and what drives the people of Intomics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Quintin Maidment
ZS@TheBlissGrp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

“Our Future is Light” Campaign Kicks off 2022 International Day of Light16.5.2022 18:03:00 EEST | Press release

An action-packed video styled as a blockbuster-movie trailer provides the linchpin for this year’s International Day of Light (IDL) campaign, “Our future is light. Play your part.” Released today, Day of Light features diverse characters successfully solving global-level problems using photonics-enabled technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005150/en/ Sponsored by SPIE, Optica, and IEEE Photonics Society, this year’s International Day of Light celebration showcases exciting, critical career opportunities in optics and photonics. (Graphic: Business Wire) Three professional societies – SPIE, the international society for optics and photonics, IEEE Photonics Society, and Optica, Advancing Optics & Photonics Worldwide – partnered to create the video and the accompanying 2022 IDL campaign. “Our future is light. Play your part” promotes the importance of light-based technologies and interesting careers

NielsenIQ Launches Retail Media Solution to Monetize Assets and Measure ROI for Retailers16.5.2022 17:01:00 EEST | Press release

Today, NielsenIQ, a global information services company, announced the launch of NielsenIQ Activate; a software-as-a-service (SaaS) solution that enables retailers to accelerate revenue opportunities through retail media and comprehensive customer insights that activate shoppers with personalized promotional offers. NielsenIQ Activate is comprised of dedicated applications for hyper-targeted audience building, offer and ads management, and end-to-end measurement. This SaaS tool, part of the NielsenIQ Connect platform, will allow retailers to create sustainable revenues by monetizing their retail media assets across physical and digital channels. Additionally, retailers will be able to boost credibility with brands and inform them of the insights they need to command their customers’ attention, act on those insights, and measure the ROI of their activities across all channels. “We are devoted to continuing our legacy by defining the next century of consumer and retail measurement,” says

TYLin and GPO Group Strategically Align16.5.2022 17:00:00 EEST | Press release

The GPO Group and Sam Schwartz, one of its operating companies, as part of a global effort to enhance connections and collaboration among companies in the Dar Group’s Global Infrastructure (GI) Pillar, are formally aligning with TYLin, the leading brand in the GI Pillar. The GPO Group and Sam Schwartz have added a TYLin “unifier” line to their names. Effective immediately, GPO will be known as GPO, A TYLin Company. Similarly, Sam Schwartz will be known as Sam Schwartz, A TYLin Company. The addition of the unifier line is part of a global strategic initiative to unify the companies in the Dar Group GI Pillar under the TYLin brand to provide more efficient access to its vast global resources and promote better collaboration among its staff. Aligning the two companies with TYLin — particularly in the rail and transit segments — means that GPO and Sam Schwartz, transportation and mobility leaders in Europe and the Americas, respectively, will expand their ability to deliver innovative thin

Xlear Teams Up With Dr. Ferrer BioPharma to Bring a Better User Experience to Nasal Hygiene16.5.2022 17:00:00 EEST | Press release

Today Xlear announced a new partnership with Dr. Ferrer BioPharma (DFBP), which will make Xlear nasal spray the first nasal hygiene tool to deploy the GentleMist nozzle—the next generation nasal spray technology that research shows achieves better compound dispersion and coverage and a better user experience. Nasal cleansing studies have found that rinsing the nose and nasal cavity is an important tool for improving health and wellbeing. Numerous clinical and lab studies have found that nasal hygiene is an important adjunct in countering rhinositus, as well as a range of bacterial and viral infections. New research, published by The European Society of Medicine found that the GentleMist nozzle achieved more uniform and more complete dispersion of nasal sprays into the nose and nasal cavity. The study also found that the new nozzle was gentler and significantly improved the user experience over typical nose spray technologies. You can read the full study by clicking here: Evaluation of

Innovative AI software for the detection of pancreatic diseases: first-in-human application successful16.5.2022 15:21:00 EEST | Press release

Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose. Early detection is crucial for the patient's chance of survival. In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis. The Medi-Globe Group, a leading international MedTech company based in Achenmühle, Bavaria, will, in cooperation with the French Institut Hospitalo-Universitaire (IHU) Strasbourg, develop the world's first AI software for the detection of diseases of the pancreas in endoscopic ultrasound (EUS) examination. The key technology here is artificial intelligence. As part of large-scale clinical studies prior to market introduction, the AI ​​software has now gone into clinical test with patients, so-called first-in-human applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005559/en/ The new AI software has the potential to revolutionize t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom